The solution, which represents a segment of Bayesian’s real-time clinical intelligence platform called the Targeted Real-time Early Warning System (TREWS), secured FDA clearance through the results of a prospective study published in Nature Medicine. During the trial, researchers found that TREWS was able to detect sepsis cases early at a sensitivity of 82%, while patients were 18% less likely to die in hospitals when doctors responded to alerts issued by the technology in a timely manner.

Researchers at Johns Hopkins University originally developed the AI-powered platform to help identify cases of sepsis faster than doctors can – potentially diminishing the burden of a disease that claims at least 11 million lives globally per year, while costing hospitals more than $50bn per year.